SEPTEMBER 22 – 25, 2016

Click on the links below to read detailed agendas for all RLDC 2016 scientific sessions and workshops. Patient and Family sessions can be viewed here

Friday, September 23, 2016

Saturday, September 24, 2016



Sunday, September 25, 2016

This year, The LAM Foundation is partnering with the Rare Lung Diseases Consortium for what will be the largest and most comprehensive international scientific research meeting focused to rare lung diseases ever held. Anticipated conference outcomes include strengthening the RLDC network of investigators, clinicians and patients, updating RLDC Clinic Directors on the latest developments in uncommon pulmonary diseases, and facilitating clinical trials in the RLDC network. This is a purpose-driven conference with an ambitious agenda that aims to improve access and outcomes for patients with rare lung disease.

The RLDC•2016 is innovative because it will create a forum for synergies between rare lung diseases with great momentum, such as LAM and pulmonary alveolar proteinosis (PAP), and those that are ripe for translation but desperately in need of focused attention, such as pulmonary Langerhan’s cell histiocytosis (PLCH) and pulmonary alveolar microlithiasis (PAM). The novel conference format will begin on day 1 with a series of 25 minute “RLD Intensives”, condensed updates on fifteen or more, scientifically interesting rare lung diseases. Day 2 will be devoted to four disease-specific workshops (LAM, PAP, PLCH and genetic lung disease) that are focused on trial and guideline development. On the morning of day 3, a Clinic Director Congress will be held to discuss network-wide opportunities for collaboration.

This year Robert Kotloff, MD, from the Cleveland Clinic will serve as Clinical Science Chair and William Parks, PhD, from Cedar-Sinai Medical Center will serve as the Basic Science Chair.

Dr. Kotloff is a transplant pulmonologist with special expertise in the evaluation and management of patients with LAM, Birt-Hogg-Dube Syndrome (BHD), and other cystic lung diseases.

Dr. Parks is an expert in the role extracellular matrix (ECM) and matrix metalloproteinases (MMPs) in lung tissue repair, host defense, fibrosis, and inflammation.

A concurrent Patient and Family Conference will feature tutorials by dozens of rare lung disease experts from all over the world speaking on topics of broad interest to families affected by rare lung diseases. To foster synergies within the rare lung disease community, all RLDC•2016 participants (scientists, clinicians and patients) dine together and are welcome to attend any and all sessions.